Date: 2014-06-24
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Astellas Pharma (Japan) Agensys (USA - CA)
Product: AGS67E
Action
mechanism: antibody drug conjugate. AGS67E is an antibody-drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. AGS67E induces potent cytotoxicity, apoptosis, and cell-cycle alterations in many non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cell lines and patient-derived samples in vitro. It also shows potent antitumor activity in NHL and CLL xenografts, including Rituxan-refractory models.
Disease: refractory or relapsed lymphoid malignancies
Therapeutic area: Cancer - Oncology
Country: Canada, USA
Trial
details: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AGS67E both without and with myeloid growth factor (GF) in subjects with refractory or relapsed lymphoid malignancies. Immunogenicity and anticancer activity of AGS67E will also be assessed. (NCT02175433)
Latest
news: * On June 24, 2014, a Phase I trial sponsored by Astellas was published on the NIH website ClinicalTrials.gov for AGS67E and is currently recruiting participants.
